🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — July 30, 2026

The six filings from Dow 30 constituents reveal a stark divergence between consumer-facing tech and industrial blue chips. Amazon and Apple delivered robust top-line growth (20% and 16% YoY, respectively), but both carry cautionary signals: Amazon's free cash flow swung to a -$7.6B outflow due to massive AI capex, while Apple's record gross margin of 50.1% was artificially boosted by ~2pp from tariff refunds, masking underlying cost pressures. Coca-Cola's chairman sold $34.3M in stock under a 10b5-1 plan, a high-materiality insider signal that warrants attention. Honeywell insider transactions were routine tax-withholding events, offering no directional insight. Alphabet's director sold a small stake, likely portfolio rebalancing. The overarching theme is that AI investment is driving a cash-flow trade-off at mega-cap tech, while consumer staples and industrials show muted insider conviction. Portfolio-level trends point to a 'growth at a cost' narrative, with investors needing to differentiate between organic strength and one-time benefits.

4 high priority 2 medium 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 30, 2026

This digest reveals a concentrated wave of distress signals across US-listed micro-cap equities, with 4 out of 5 filings detailing imminent delisting risks due to non-compliance with minimum bid price rules. The cluster of Nasdaq and NYSE deficiency notices received within a single week (July 24-29, 2026) indicates a systemic liquidity and valuation crisis among small-cap companies, rather than isolated incidents. A critical pattern emerges: while companies like Curis have technically regained compliance, they face a Draconian 'one-year Discretionary Panel Monitor' with zero tolerance for future deficiencies, effectively placing them on a permanent watchlist. The most severe case is Woodbridge Liquidation Trust, which has formally acknowledged it cannot complete its liquidation by the original deadline, seeking a three-year extension to 2030 due to a lingering construction defect claim, signaling a deeply impaired asset recovery process. The data shows no positive period-over-period trends or insider buying to offset these bearish signals; the dominant themes are capital structure erosion, regulatory overhang, and a lack of credible turnaround catalysts. The market implication is clear: these securities face a high probability of structural impairment, with delisting representing a catastrophic loss of liquidity and access to public capital markets.

5 high priority 5 total filings
· daily

US SEC Filings Daily Market Digest — July 30, 2026

Today's 50 filings reveal a market bifurcated between robust top-line growth and mounting margin pressures. While 8 of 10 reporting companies posted revenue gains (avg +9.8% YoY), 5 of 10 saw margin compression averaging -120 bps, driven by cost inflation and heavy investment. A surge in M&A activity (CRH's $8.5B Arcosa deal, SoftVest's $2.2B PBT combination, and MiMedx's Sanara acquisition) signals aggressive capital deployment in infrastructure and energy, while the tech sector shows a stark divergence between data center strength (WESCO +45% YoY, Trane +130% bookings) and consumer-facing weakness (Ambev CAC -5.4% volume, Magnum Americas -1.1% revenue). Insider activity is notably absent across filings, but capital allocation patterns are clear: buybacks and dividends are being prioritized by cash-rich firms (WTW +$1.5B buyback, Virtu $0.24 dividend), while pre-revenue biotechs (Braveheart, NanoViricides) rely on dilutive offerings. The most critical development is the Eli Lilly acquisition of atai Life Sciences at $6.75/share plus CVRs, providing a clear liquidity event in the psychedelic therapeutics space. Overall, the market is rewarding scale and pricing power while punishing margin erosion, with infrastructure and AI-related plays emerging as the clear winners.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 30, 2026

The three Consumer Discretionary filings reveal a sector bifurcating between AI-driven growth and legacy brand struggles. Amazon's 20% revenue surge and 43% operating income jump, fueled by AWS's 37% growth and massive AI capex, contrast sharply with Yum! Brands' mixed results where Taco Bell (+7% same-store sales) and KFC (+6% system sales) outperformed while Pizza Hut declined 2%. The most critical development is Yum!'s definitive agreement to sell Pizza Hut, signaling a strategic pivot to higher-growth concepts. Meanwhile, Booking Holdings' director sold $1M in stock under a 10b5-1 plan, adding a note of caution in the travel sector. Portfolio-level trends show strong top-line growth (Amazon +20%, Yum! +5% system sales) but diverging margin trajectories, with Amazon's operating margin expanding 220 bps while Yum!'s Pizza Hut margins compressed 14%. The overarching theme is that AI and digital transformation investments are creating winners and losers, with capital allocation increasingly favoring high-growth segments over legacy assets.

1 high priority 2 medium 3 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 30, 2026

The S&P 500 Healthcare sector is showing a clear divergence between top-line growth and bottom-line profitability. While 5 of 6 reporting companies posted revenue growth (Cigna +7%, Regeneron +17%, Bristol Myers +6%, Baxter +5%), margin compression is a dominant theme, with Regeneron's GAAP gross margin falling 500 bps YoY and Bristol Myers' gross margin contracting 120 bps. Forward-looking data reveals a bifurcated outlook: Cigna and Bristol Myers raised full-year guidance, while Baxter's adjusted EPS guidance implies a potential decline. Insider activity is limited but notable, with Edwards Lifesciences' CVP selling a small position. Capital allocation patterns are shifting dramatically—Cigna slashed buybacks by 90% YoY ($250M vs $2.58B), while Regeneron accelerated repurchases to nearly $2B in H1 2026. The sector is investing heavily in R&D and M&A, with Bristol Myers' R&D up 15% and Regeneron's IPR&D expenses surging 1,170%. The overall sentiment is mixed, with strong revenue growth offset by rising costs, margin pressure, and strategic repositioning.

5 high priority 6 medium 11 total filings
· daily

US Earnings Financial Results SEC Filings — July 30, 2026

This digest of 50 pre-analyzed regulatory filings for the period ending June 30, 2026, reveals a market characterized by a stark divergence in performance. While top-line revenue growth is common, with companies like Quanta Services (+41.1% YoY), PBF Energy (+56.2%), and Meta Platforms (+28%) reporting strong gains, profitability is under significant pressure from rising costs, restructuring charges, and increased capital expenditure. A key theme is the 'growth at a cost' dynamic, where aggressive investment in R&D, M&A, and infrastructure is compressing margins and straining cash flows, as seen with Meta, NextDecade, and Life Time Group. The energy sector shows a dramatic turnaround from losses to profits, while the industrial and construction sectors are booming. However, several companies are facing headwinds from currency translation, rising credit losses, and declining core business segments, creating a complex and selective investment landscape. The most critical developments include a massive insider sale at Regeneron, a significant turnaround at PBF Energy, and a sharp profit decline at Pilgrim's Pride, each with distinct market implications.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 30, 2026

The six proxy filings reveal a bifurcated governance landscape: two companies (Zoned Properties and Ocugen) are pursuing transformative but dilutive or conflicted transactions, while others (Lamb Weston, Mexco Energy) focus on routine governance and compensation updates. Period-over-period comparisons are limited as most filings lack explicit financial trends, but capital allocation patterns are clear—Ocugen relies heavily on equity-linked financing (convertible notes requiring share authorization), while Zoned Properties is exiting operations via a management-led buyout. Insider activity is most notable at Zoned Properties, where the buyer group (senior management) creates a severe conflict of interest. Forward-looking data highlights key catalysts: Ocugen's BLA submissions by 2028 and Lamb Weston's new equity plan. The overarching theme is governance risk: two of the six filings involve related-party transactions or dilutive capital raises that require close shareholder scrutiny.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 30, 2026

The IPO pipeline digest for July 30, 2026, reveals a mixed landscape with two new S-1 filings and one routine S-4 filing. Presidio Production Co's S-1 shows strong top-line growth (revenue +15% YoY to $5.0B) and margin expansion (net income +22% YoY to $1.2B), but is tempered by a 7% production decline in its key Oklahoma region, which now contributes 35% of total BOE (down from 40%). Laser Photonics Corp's S-1 highlights significant dilution risk from selling stockholders, including affiliates of placement agent H.C. Wainwright, with no proceeds to the company from share sales. Comcast's S-4 is a routine exchange offer with low materiality. Key period-over-period trends include Presidio's improved operational efficiency (net income growth outpacing revenue growth by 700 bps) and a shift in production mix away from Oklahoma. The most critical development is the potential overhang from Laser Photonics' secondary offering, which could pressure the stock. Portfolio-level patterns show a divergence between capital-intensive energy IPOs (high capex, production risks) and small-cap tech resale filings (dilution risks).

3 high priority 3 total filings
· daily

USA Institutional Investor Activity — July 30, 2026

This digest covers a single 13F-HR filing from Quadrant Private Wealth Management, LLC for the period ended June 30, 2026, filed on July 30, 2026. The filing is a point-in-time holdings snapshot, providing no prior-period comparisons for direct percentage changes. The portfolio shows a balanced mix of mega-cap tech (NVIDIA, Netflix), fixed income ETFs (iShares US Treasury Bond), broad market ETFs (SPDR S&P 500), and thematic exposure (iShares Bitcoin Trust). The lack of prior or aggregate portfolio value data limits trend analysis, but the disclosed positions suggest a growth-with-income tilt and cautious cryptocurrency exposure. The neutral sentiment and moderate materiality score (5/10) reflect the filing's limited forward-looking or comparative value. Key actionable insights derive from the portfolio's composition and implied sector weightings, which can be used to gauge institutional conviction in specific names and asset classes.

1 medium 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 30, 2026

The regulatory filings from July 24-29, 2026 reveal a concentrated wave of Nasdaq and NYSE listing deficiencies among small-cap and micro-cap companies, signaling heightened regulatory scrutiny and financial fragility in this segment. Four companies—Flux Power Holdings, Curis, Genprex, and Lument Finance Trust—all received or resolved notices related to sub-$1.00 bid prices, a common stress indicator for distressed equities. Genprex's situation is the most acute, having implemented a 1-for-22 reverse stock split and facing an immediate delisting threat under new Nasdaq rules regarding market value of listed securities. Curis narrowly avoided delisting but enters a strict one-year Discretionary Panel Monitor with zero tolerance for future non-compliance. Lument Finance Trust, a mortgage REIT, faces a six-month NYSE cure period, while Flux Power has a 180-day window. The cluster of filings suggests a broader market trend of low-priced stocks struggling to maintain exchange listings, which could trigger forced selling, dilutive reverse splits, or eventual delisting. No period-over-period financial comparisons, insider trading activity, or forward-looking guidance were provided in these filings, limiting quantitative trend analysis but amplifying the binary nature of the risks—compliance or delisting—for each issuer. The materiality is high (8-9/10) for all four, as loss of listing would severely impair liquidity and access to capital for these already vulnerable companies. Investors should view this cluster as a systemic risk signal for the micro-cap ecosystem, where regulatory tightening is accelerating the purge of non-compliant names.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 30, 2026

The July 30, 2026, digest of 34 filings reveals a market characterized by strong operational performance in select industrial and consumer names, contrasted with significant leadership transitions and strategic pivots across technology and healthcare. Period-over-period data shows robust revenue growth at MasTec (+23% YoY), Steven Madden (+19.1% YoY), and PTC Therapeutics (+102% YoY), while Forrester Research (-10.3% YoY) and legacy pharma products at PTC declined. The most critical developments include a major CEO succession at Cabot Corp and Stride, Inc., alongside a strategic board appointment at BrainStorm Cell Therapeutics with former FDA leadership. Portfolio-level patterns indicate a strong focus on AI and operational efficiency, with several companies restructuring leadership to accelerate tech-driven growth, while insider activity remains largely absent from these filings, suggesting a focus on strategic board refreshment rather than management conviction signals.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 30, 2026

This digest of 34 SEC filings reveals a significant wave of board and leadership changes across US-listed companies, with a clear emphasis on strategic succession planning and the addition of independent directors with deep operational and financial expertise. Key themes include the appointment of former CEOs and CFOs from major firms (e.g., MGM, Atkore, Affirm) to boards, signaling a focus on operational excellence and capital allocation. Period-over-period data from a subset of companies shows a mixed earnings picture: while MasTec and Steven Madden reported strong revenue growth (23% and 19.1% YoY, respectively), Forrester Research saw a 10.3% revenue decline, and PTC Therapeutics' legacy products continued to erode. Insider activity was limited, but the CEO succession at Stride, Inc. and Cabot Corp. are notable for their orderly transitions. The most critical development is the strategic pivot at BrainStorm Cell Therapeutics, appointing a former FDA official as Executive Chairman to navigate a pivotal Phase 3b trial. Overall, the filings suggest a market focused on refreshing leadership to navigate a complex operating environment, with a mix of growth, transition, and risk.

34 high priority 34 total filings
· daily

USA Insider Trading Pulse — July 30, 2026

Insider trading activity on July 30, 2026, reveals a pronounced bi-directional signal in the US equity markets. A dominant and highly material bearish event is the massive stock sale by Coca-Cola's Chairman James Quincey, who netted ~$34.3M in a pre-planned transaction, marking the largest dollar-value insider sale of the day. In contrast, a defensive and opportunistic buying pattern emerged across several financial and value-oriented firms, including Albertsons, Parke Bancorp, and Vista Credit Strategic Lending Corp, where CEOs and directors added to their positions. A significant cluster of neutral, large-scale dispositions at Open Lending Corp suggests a major corporate event or restructuring, involving multiple C-suite executives and directors. The data indicates a pullback in consumer-facing and tech sectors through insider selling, while select financial and energy pockets exhibit insider confidence. Period-over-period comparisons were largely absent from the filings, limiting trend analysis, but the transactional data provides a clear snapshot of immediate management sentiment.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 30, 2026

The July 30, 2026 M&A digest reveals a bifurcated SPAC market: two newly-formed SPACs (B&R Technology, Lakeshore III) successfully raised capital and amended charters to pursue targets, while two existing SPACs (Keen Vision, DT Cloud Star) face imminent delisting for failing to complete business combinations, signaling a harsh penalty for prolonged deal inactivity. In the operational M&A space, two high-value transactions closed—Etsy’s $1.4B sale of Depop to eBay and Avanos Medical’s $1.27B take-private by AIP—both generating significant cash proceeds for the sellers. AiRWA’s $50M acquisition of Hong Kong Best Life introduces a unique crypto-based payment structure (USDT) and contingent earn-outs, while Iron Horse Acquisition II’s target, Electra Vehicles, secured a marquee client win (Propel Industries) for its battery AI platform. The overall period shows no material revenue or margin trends from these filings, as most are event-driven 8-Ks, but the insider activity and forward-looking data point to a clear catalyst calendar around shareholder votes and SEC reviews for pending deals.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 30, 2026

Overnight filings reveal a market bifurcated between robust operational performance and cautious insider behavior. While 15+ companies reported strong YoY revenue growth (e.g., WESCO +13%, Virtu Financial +19%, Yum China +13%), a significant wave of insider selling—particularly at Natera (6 executives), CoreWeave, and Roivant Sciences—signals potential valuation concerns or profit-taking at elevated levels. The most material corporate action is the $8.5B Arcosa acquisition by CRH, reinforcing a consolidation trend in building materials. Mixed sentiment dominates, with many companies showing top-line strength but margin compression (e.g., Solstice Advanced Materials, Magnum Ice Cream) or declining cash flows (CRH, WESCO). The IPO pipeline is active with Braveheart Bio filing for a $319M offering. Key themes include data center/AI infrastructure demand (WESCO, AITX), margin discipline challenges, and a divergence between reported earnings and underlying cash generation.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 29, 2026

This July 29, 2026 digest covers three FDA approvals, all classified as 'Other' (FALLBACK type), with zero NMEs, zero biosimilars, and zero label expansions. The period lacks a dominant therapeutic area theme, as the approvals span neurology (DIAZEPAM), endocrinology (INSULIN ASPART-FSAN), and neurology (TOPIRAMATE). The highest-conviction signal is the bullish NME approval of INSULIN ASPART-FSAN (GARZULYS) by EMERGE BIOSCIENCE PTE. LTD., representing a potential new entrant in the insulin market, though commercial details remain undisclosed. Key risks include the lack of clarity on pricing, exclusivity, and market positioning for all three drugs, limiting actionable investment conclusions. The overall signal mix is 1 bullish, 0 bearish, and 2 neutral, reflecting a low-impact period for biotech small-cap investors.

3 total filings
· daily

New Drug Approvals (Original) — July 29, 2026

During the single-day period of July 29, 2026, the FDA approved 3 non-NME, non-biosimilar, non-label-expansion drugs—classified as 'Other' (likely generic or follow-on approvals). The mix featured zero new molecular entities, zero biosimilars, and zero label expansions, indicating a low-catalyst session for institutional investors. The highest-conviction signal was EMERGE BIOSCIENCE PTE. LTD.'s approval of INSULIN ASPART-FSAN (branded GARZULYS), classified as an NME approval but flagged as a 'Fallback' type, suggesting potential classification ambiguity; this represents a potential entry into the $20B+ insulin market. The remaining approvals—DIAZEPAM by LUPIN and TOPIRAMATE by BIOCON PHARMA—are low-materiality generic entries generating neutral signals. Key watch item: clarify whether EMERGE's INSULIN ASPART-FSAN holds NCE exclusivity or faces immediate competition given its Fallback designation.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — July 29, 2026

The digest covers a single $97.4 million civilian contract awarded to Tutor Perini Corporation by the Department of Homeland Security (Coast Guard) for residential construction in Kodiak, Alaska. This is a 100% civilian infrastructure award with no defense exposure, reflecting stable but non-growth-oriented federal housing spending. The highest-conviction signal is neutral: the fixed-price design-build structure in a remote location introduces execution risk, while the full-and-open competition suggests no durable competitive moat. Key risk is the high pricing risk from remote logistics and the fact that only $3 million has been outlayed, leaving $94 million in future revenue subject to performance milestones.

1 total filings